These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16890327

  • 1. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK, Dessalew N, Bharatam PV.
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [Abstract] [Full Text] [Related]

  • 2. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N, Bharatam PV.
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [Abstract] [Full Text] [Related]

  • 3. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
    Dessalew N, Singh SK.
    Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
    [Abstract] [Full Text] [Related]

  • 4. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK, Dessalew N, Bharatam PV.
    Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
    [Abstract] [Full Text] [Related]

  • 5. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM, Ghoshal N.
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
    Aubry C, Wilson AJ, Jenkins PR, Mahale S, Chaudhuri B, Maréchal JD, Sutcliffe MJ.
    Org Biomol Chem; 2006 Mar 07; 4(5):787-801. PubMed ID: 16493461
    [Abstract] [Full Text] [Related]

  • 7. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P, Chen WN, Xiao GK, Sun PH, Chen WM.
    Bioorg Med Chem Lett; 2010 Nov 15; 20(22):6764-72. PubMed ID: 20869873
    [Abstract] [Full Text] [Related]

  • 8. Exploring QSAR on 3-aminopyrazoles as antitumor agents for their inhibitory activity of CDK2/cyclin A.
    Samanta S, Debnath B, Basu A, Gayen S, Srikanth K, Jha T.
    Eur J Med Chem; 2006 Oct 15; 41(10):1190-5. PubMed ID: 16806589
    [Abstract] [Full Text] [Related]

  • 9. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
    Caballero J, Fernández M, González-Nilo FD.
    Bioorg Med Chem; 2008 Jun 01; 16(11):6103-15. PubMed ID: 18468903
    [Abstract] [Full Text] [Related]

  • 10. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
    García MD, Wilson AJ, Emmerson DP, Jenkins PR, Mahale S, Chaudhuri B.
    Org Biomol Chem; 2006 Dec 21; 4(24):4478-84. PubMed ID: 17268643
    [Abstract] [Full Text] [Related]

  • 11. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA, Chen JJ, Qian HY, Pan YL, Chen JZ.
    Mol Biosyst; 2016 Apr 21; 12(4):1250-68. PubMed ID: 26883408
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA, Ismail NS.
    Eur J Med Chem; 2011 Dec 21; 46(12):5825-32. PubMed ID: 22000924
    [Abstract] [Full Text] [Related]

  • 13. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
    Yuan H, Liu H, Tai W, Wang F, Zhang Y, Yao S, Ran T, Lu S, Ke Z, Xiong X, Xu J, Chen Y, Lu T.
    SAR QSAR Environ Res; 2013 Oct 21; 24(10):795-817. PubMed ID: 23941641
    [Abstract] [Full Text] [Related]

  • 14. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP, McInnes C.
    IDrugs; 2006 Apr 21; 9(4):273-8. PubMed ID: 16596481
    [Abstract] [Full Text] [Related]

  • 15. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
    Tsou HR, Otteng M, Tran T, Floyd MB, Reich M, Birnberg G, Kutterer K, Ayral-Kaloustian S, Ravi M, Nilakantan R, Grillo M, McGinnis JP, Rabindran SK.
    J Med Chem; 2008 Jun 26; 51(12):3507-25. PubMed ID: 18494457
    [Abstract] [Full Text] [Related]

  • 16. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM.
    Chem Biol; 2006 Feb 26; 13(2):201-11. PubMed ID: 16492568
    [Abstract] [Full Text] [Related]

  • 17. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
    Aubry C, Wilson AJ, Emmerson D, Murphy E, Chan YY, Dickens MP, García MD, Jenkins PR, Mahale S, Chaudhuri B.
    Bioorg Med Chem; 2009 Aug 15; 17(16):6073-84. PubMed ID: 19632122
    [Abstract] [Full Text] [Related]

  • 18. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD, Zhang YE, Qin F, Chen WN, Jiang WM, Fang Z, Liang XL, Zhang Q, Li J.
    J Cancer Res Clin Oncol; 2024 Jun 10; 150(6):302. PubMed ID: 38856753
    [Abstract] [Full Text] [Related]

  • 19. 3D QSAR studies on GSK-3 inhibition by aloisines.
    Zeng M, Jiang Y, Zhang B, Zheng K, Zhang N, Yu Q.
    Bioorg Med Chem Lett; 2005 Jan 17; 15(2):395-9. PubMed ID: 15603961
    [Abstract] [Full Text] [Related]

  • 20. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
    Sims PA, Wong CF, McCammon JA.
    J Med Chem; 2003 Jul 17; 46(15):3314-25. PubMed ID: 12852762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.